Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career areas of impact
Students
Re-Ignite Program
Contract & freelance partner opportunities
Career stories
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career areas of impact
Students
Re-Ignite Program
Contract & freelance partner opportunities
Career stories
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Menu
Search Query
Submit Search
Dictate search request
Search Results
No Matching Results
Recently Viewed
Listening...
Show Search
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
1,938 results
Date
All Dates (1938)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1938)
Corporate (132)
ESG (1)
Financial (290)
Global Health Equity (59)
Leadership (20)
Medical technologies (261)
Pharmaceuticals (873)
Research (42)
1,938 results
Filters
Date
All Dates (1938)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1938)
Corporate (132)
ESG (1)
Financial (290)
Global Health Equity (59)
Leadership (20)
Medical technologies (261)
Pharmaceuticals (873)
Research (42)
Sort By:
Relevance
Newest
Relevance
Oldest
February 10, 2017
Financial Conflicts of Interest Policy
Read more
March 23, 2017
Social Media Community Guidelines
Read more
January 30, 2024
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Data supporting the application showed the addition of DARZALEX FASPRO® to lenalidomide, bortezomib and dexamethasone (VRd) induction and consolidation and lenalidomide maintenance therapy reduced the risk of progression or death by 58 percent compared to standard of care If approved, the DARZALEX FASPRO®-based regimen has the potential to provide an effective quadruplet therapy for many patients with newly diagnosed multiple myeloma who are eligible for transplant
Read more
November 16, 2023
Johnson & Johnson to Host Enterprise Business Review
Read more
November 14, 2023
New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)
Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen continues commitment to supporting PAD patients with ongoing research to help understand this undertreated and underdiagnosed disease1
Read more
October 10, 2022
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either treatment alone (31.0 percent and 20.8 percent, respectively) at 38 weeks1
Read more
September 28, 2022
Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
Modern name, purpose, and visual identity mark inspiring next chapter for maker of iconic, trusted brands, including Tylenol, Neutrogena, Listerine, and Band-Aid Brand
Read more
September 1, 2022
Johnson & Johnson Statement on New Hampshire Opioid Settlement Agreement
Read more
August 17, 2022
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
Read more
August 11, 2022
Johnson & Johnson Consumer Health to Transition Global Baby Powder Portfolio to Cornstarch
Read more
Load More
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue